Biosimilars
35 results
Applied filters
Preparing to use ustekinumab biosimilar
29 July 2025Introducing biosimilar ustekinumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Good governance when implementing ustekinumab biosimilar
29 July 2025Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for ustekinumab biosimilars
29 July 2025Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.
Understanding data exclusivity and market protection
11 July 2025Data exclusivity and market protection periods prevent generic or biosimilar competition for at least 10 years after the originator medicine is licensed.
Understanding patents
11 July 2025Patents allow the inventor a finite period of monopoly in exchange for publicising the idea. We explain how they work with respect to medicines.
Good governance when implementing natalizumab biosimilar
11 December 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.
The licence and supporting evidence for eculizumab biosimilars
11 September 2024Two licensed eculizumab biosimilars are available: Bekemv and Epysqli. Learn about the licensed indications, supporting evidence and key differences.
Preparing to use eculizumab biosimilar
12 March 2024Introducing biosimilar eculizumab needs planning. Work with the multidisciplinary team to ensure familiarity with the area and develop an implementation plan.
Good governance when implementing eculizumab biosimilar
6 March 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
The licence and supporting evidence for natalizumab biosimilar
14 February 2024One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.